IP Library Granted Patent US 7,226,995
Granted Patent B2
US 7,226,995 · App. 10/947,267 · Granted Jun 5, 2007

Use of C-reactive protein to treat immune complex-mediated renal disease

Assignee: STC.UNM
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,995
App. No.
10/947,267
Granted
Jun 5, 2007
Kind
B2
Abstract

The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.

Claims (10)

1. A method of treating kidney disease associated with glomerulonephritis in an animal subject in need of treatment comprising administering an effective amount of a therapeutic material chosen from a C-reactive protein, a metabolite of C-reactive protein, and a combination thereof to the animal subject for a time and under conditions effective to mitigate kidney disease associated with glomerulonephritis.

2. The method of claim 1 , wherein the animal subject is a mammal.

3. The method of claim 1 , wherein the animal subject is a human.

4. The method of claim 3 , wherein the animal subject is a mouse.

5. The method of claim 4 , wherein the C-reactive protein is administered in a dose of about 200 μg.

6. The method of claim 1 , wherein the administering is effected via a transcutaneous medicator.

7. The method of claim 1 , wherein the administering is effected via subcutaneous injection.

8. The method of claim 1 , wherein the administering is effected intravenously.

9. A method of treating kidney disease associated with systemic lupus erythematosus in a patient in need of treatment, comprising administering an effective amount of a therapeutic material chosen from a C-reactive protein, a metabolite of C-reactive protein, and a combination thereof to the patient for a time and under conditions effective to mitigate kidney disease associated with systemic lupus erythematosus.

10. A method of treating kidney disease associated with proteinuria in a patient in need of treatment, comprising administering an effective amount of a therapeutic material chosen from a C-reactive protein, a metabolite of C-reactive protein, and a combination thereof to the patient for a time and under conditions effective to mitigate kidney disease associated with proteinuria.

Assignments (6)
CONFIRMATORY LICENSE Recorded Nov 2, 2011
From: UNIVERSITY OF NEW MEXICO ALBUQUERQUE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027160/0173 →
CHANGE OF NAME Recorded Feb 25, 2008
From: SCIENCE & TECHNOLOGY CORPORATION @UNM
To: STC.UNM
Reel/Frame 020553/0099 →
CHANGE OF NAME Recorded Nov 27, 2006
From: SCIENCE & TECHNOLOGY CORPORATION @ UNM
To: STC.UNM
Reel/Frame 018554/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2006
From: NEW MEXICO, UNIVERSITY OF
To: SCIENCE & TECHNOLOGY CORPORATION @ UNM
Reel/Frame 017530/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2005
From: NEW MEXICO, UNIVERSITY OF
To: SCIENCE & TECHNOLOGY CORPORATION @ UNM
Reel/Frame 016737/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2004
From: DU CLOS, TERRY; MOLD, CAROLYN
To: UNIVERSITY OF NEW MEXICO
Reel/Frame 015994/0757 →
Continuity (2)
Provisional Application 6051412200 · Oct 23, 2003
Related Publication 20050281807A1 · Dec 22, 2005